Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
ReviewHumans
- Design
- Review
- Subjects
- Narrative review
- Dose used in the study
- Up to 1.8 g a day in the trials cited
- Duration
- Not applicable
- What was measured
- The case for palmitoylethanolamide in glaucoma, diabetic retinopathy and uveitis, drawing on the eye trials and the wider trial record
What the authors reported
Palmitoylethanolamide has been tested in at least nine double-blind placebo-controlled studies since the 1970s, two in glaucoma, and found safe and effective up to 1.8 g a day, the authors state. They name commercial products, including ones notified in Italy.
Limits of this study
A narrative review whose abstract names commercial products. It does not give trial sizes, results or quality ratings, and funding and conflicts are not stated in the abstract.
Source
PubMed 26664738 · doi:10.1155/2015/430596
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.